天天舔天天爽_视频日韩_成人网线_天天草草草_免费一级在线观看_色综合色综合色综合色综合

瑞典Cellartis AB
阿斯利康與瑞典Cellartis公司表示，二者已簽署了一項協議，延長目前正在進行的一項合作。該合作旨在開發基于人類胚胎干細胞生成的肝及心肌細胞的改良安全性篩選系統。

此次簽署的協議表明兩家公司將延長于2006年7月簽署的一項為期兩年的合作協議，該協議旨在研究從已建立的人類胚胎干細胞（hESC）生產線上獲得的細胞是否能夠被分化為機能人類肝細胞及心肌細胞。兩家公司表示：“分化技術的進一步改進，將使科學家能夠在藥物開發過程更早時期，更好地預測藥物的代謝以及其對人類肝及心臟可能產生的副作用。”

Cellartis首席執行官Mats Lundwall表示，此項合作“目前正進入令人興奮的階段”，其還表示：“我們一直在通過此類交易確認我們作為hESC領域領軍人物的聲譽。”

阿斯利康負責開發事務的執行副總裁Jan Lundberg表示：“如果我們能夠確實成功地建立一個分化胚胎干細胞的穩定供應，我們將能夠更準確地檢測出新藥的副作用。”其還表示：“這一突破可能會降低損耗率從而提高研發生產力，并最終為患者提供更安全的藥物。盡管依然存在重大科學障礙，但我們正在取得良好的進展并獲得寶貴的經驗。”（


Cellartis AB is a Swedish/British biotechnology company focused on human embryonic stem (hES) cells and technology for drug discovery research, toxicity testing and regenerative medicine. The company is the world’s largest single source of ethically derived hES cell lines and has developed more than 30 ethically derived cell lines. The main business objective of Cellartis is to develop hepatocytes and cardiomyocytes from the proprietary stem cells for use as tools in drug discovery.

The company's strategy is to accelerate product development by working in partnership with academia and industry towards advanced stem cell products and technologies. Cellartis was founded in 2001 and is located in state of art facilities in G?teborg, Sweden and in Dundee, UK. The laboratories are prepared to meet the EU guidelines for current Good Manufacturing Practice (cGMP).

Moreover, Cellartis has implemented a quality system and laboratory standards that meet the foreseeable future demands. Cellartis is focused on quality and scale-up production, which are crucial success factors for future growth. Therefore, Cellartis has expanded its operation into automated cell production and built the world's first production facility to make large volumes of hES cells.

Cellartis welcomes strategic alliances and are actively seeking collaboration partners from the pharmaceutical and biotechnology industries.